Developing scalable cell replacement therapies for the world

Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and has built collaborations with pioneers and leaders in the space. Our long-term vision is to create a scalable cell therapy platform to treat incurable diseases and democratize access to these newer technologies for the bottom 99 % of the population globally.

We have embedded manufacturing and quality processes in the platform which will enable us to create a virtuous cycle of innovation and decrease the time to market for such therapies. Our lead product out of the platform is Eyecyte-RPE aimed at treating Dry AMD (Age-related Macular Degeneration). Dry AMD is the largest cause of incurable blindness in people above 60 and affects roughly 170 million people worldwide. Pivotal efficacy and safety studies for this product have started at Oregon Health and Science University and we expect to begin first in man studies for the same in 2022.

Enroll in our Global Research Alliance

Recent Scientific Papers

Harshini Surendran, Saurabh Kumar, Swathi…

SARS-CoV-2 infection of human-induced pluripotent stem cells-derived lung lineage cells evokes inflammatory and chemosensory responses by targeting mitochondrial pathways

 23 April 2022

Konala VBR, Nandakumar S, Surendran…

Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies.

 Toxicol Appl Pharmacol. 2021;433:115792.

Nandakumar S, Shahani P, Datta…

Interventional Strategies for Parkinson Disease: Can Neural Precursor Cells Forge a Path Ahead?

 ACS Chem Neurosci. 2021;12(20):3785-3794.

Pal R

A small-molecule cocktail that beats cellular stress.

 Nat Methods. 2021;18(5):457-458

Battu R, Mallipatna A, Elackatt NJ, Schouten JSAG,

Webers Challenges of managing retinal dystrophies: an experience from south India. Ophthalmic Genetics.

2018. 39(1): 1-3.

Surendran H, Rathod RR. Pal R.

Generation of transplantable Retinal Pigmented Epithelial (RPE) cells for treatment of Age-related Macular Degeneration (AMD

2018. Meth Mol Biol. (Accepted).

Battu R, Mohan A, Khanna A, Kumar A, Shetty R

Retinal oxygen saturation in Retinitis Pigmentosa and macular dystrophies in Asian Indian eyes. Invest Ophthalmol Vis Sci. 2015.

56(5): 2798-802.

Battu R, Khanna A, Hegde B, Berendschot TT, Grover G, Schouten JS.

Correlation of Structure and Function of the Macula in patients with Retinitis Pigmentosa. Eye (Lond).

2015. 29(7): 895-901.
View all Scientific Papers

EyestemFollow

Eyestem
Eyestem@EyestemResearch·
1 Jul

Hear a podcast by our founder @jogin_desai at @thepodiumIn on the Eyestem journey and the underlying conditions that we are hoping to treat @CCAMP_Bangalore

Twitter 1542804449172721665
Retweet on TwitterEyestem Retweeted
ABLE@able_indiabio·
22 Jun

Know more about @EyestemResearch cells replacements therapies to treat some of the incurable diseases for the world.
Register today @ https://bit.ly/3x0PZrZ
@Ktech_biotech @DBTIndia @BIRAC_2012 @ICMRDELHI @able_president @AbleCouncil

Twitter 1539472375766740993

Career Openings

Research Associate

Project: Hands-on experience in gene editing tools like ZFN, TALEN, CRISPR/Cas9 preferred

Junior / Senior Research Fellow

Project: Hands-on experience in mammalian cell and tissue culture (preferably with stem or progenitor cells) and basic cell biology techniques

View all